ANIP

ANIB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+1

B+

Bull case

30%

Probability

Target price

$102.00

+36.6% vs current

Most likely

Base case

45%

Probability

Target price

$92.00

+23.2% vs current

B-

Bear case

25%

Probability

Target price

$72.00

-3.5% vs current

AI sentiment snapshot

Latest data as of 2026-05-09

AI commentary

Primary-source evidence turned more constructive after the May 8 earnings release, but this is still an early T+1 monitoring setup rather than a fully confirmed rerating. News tone was positive on the beat and raised outlook, yet the price reaction was not clean follow-through: shares opened at $87.76 and hit $90.12 intraday after earnings, but the latest trade was $81.86 versus the $83.91 May 7 anchor. Post-print analyst target and estimate revisions were not reliably available at this checkpoint, which lowers confidence despite the positive operating update.

RankAlpha Sentiment Codex - 2026-05-09

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-08catalystQ1 beat-and-raise resets near-term setupHigh impact

ANI reported Q1 2026 net revenue of $237.5M, adjusted EBITDA of $63.0M, adjusted EPS of $2.05, raised 2026 revenue guidance to $1.08B-$1.14B, raised EBITDA guidance to $285M-$300M, raised adjusted EPS guidance to $9.19-$9.69, and authorized a $100M buyback; this is the main post-earnings positive signal, but the T+1 read still needs confirmation from follow-through trading and later analyst revisions [#8-K-2026-05-08].

2026-08-15catalystCortrophin commercial expansion remains the core earnings leverHigh impact

Management cited 42.1% year-over-year Cortrophin Gel growth to $75.1M, continued demand momentum across target indications, and a mostly onboarded commercial team for acute gouty arthritis flares expected to begin broader HCP reach in the back half of Q2; if execution holds, Cortrophin can keep driving mix toward Rare Disease and support the raised full-year outlook [#8-K-2026-05-08].

2026-09-30eventQ3 ILUVIEN Phase 4 readout offers pipeline confirmationHigh impact

The company said it is on track to announce results from the Phase 4 SYNCHRONICITY trial in NIU-PS at a medical conference in Q3 2026; a clean readout would add a second forward hook beyond Cortrophin, while disappointment would reinforce the single-franchise concentration concern [#8-K-2026-05-08].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-09 • Updated nightlySource: Internal modelMethodology